Department of Orthopaedic Surgery, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. E-mail address for P.E. Blazar:
333 Harrison Street, Apartment #745, San Francisco, CA 94105. E-mail address:
J Bone Joint Surg Am. 2015 Oct 7;97(19):1563-70. doi: 10.2106/JBJS.N.01162.
Corticosteroid injections are commonly used in the treatment of carpal tunnel syndrome in adults. This study sought to determine success rates early on and at one year postoperatively of a single corticosteroid injection while identifying prognostic indicators for symptom recurrence and repeat intervention.
Fifty-four consecutive wrists in forty-nine patients with carpal tunnel syndrome treated with a single corticosteroid injection were prospectively enrolled. Demographic data and information on comorbidities were identified with a study-specific questionnaire. The Boston Carpal Tunnel Questionnaire was administered prior to injection. Patients returned to clinic at six weeks and were contacted at three, six, nine, and twelve months post-injection to determine symptom and intervention status. Kaplan-Meier analysis and Cox regression modeling were used to estimate recurrence rates and to identify predictors of symptom recurrence and repeat intervention.
Fifty-four symptomatic wrists in forty-nine patients with a mean age of fifty-three years were included. Two patients (two wrists) were lost to follow-up. Patients reported symptom recurrence in thirty-one wrists at a median duration of 155 days post-injection. Nineteen wrists underwent carpal tunnel release at a median time of 181 days after the injection. No patient underwent a repeat injection. In our study, diabetic patients were at a 2.6-fold greater risk of reporting recurring symptoms within a one-year follow-up period. Survivorship free from symptom recurrence was 53% at six months and 31% at twelve months; survivorship from repeat intervention was 81% at six months and 66% at twelve months.
A single injection achieved symptom relief in 79% of patients at six weeks; these results were maintained in 31% of patients at twelve months. Diabetic patients were at higher risk of symptom recurrence.
皮质类固醇注射在成人腕管综合征的治疗中很常用。本研究旨在确定单次皮质类固醇注射后早期和一年后的成功率,并确定症状复发和重复干预的预测指标。
前瞻性纳入 49 例 54 只腕部接受单次皮质类固醇注射治疗的腕管综合征患者。采用专门的研究问卷确定人口统计学数据和合并症信息。在注射前进行波士顿腕管问卷评估。患者在 6 周时返回诊所,并在注射后 3、6、9 和 12 个月时联系,以确定症状和干预情况。采用 Kaplan-Meier 分析和 Cox 回归模型来估计复发率,并确定症状复发和重复干预的预测因素。
纳入了 49 例平均年龄为 53 岁的 54 只症状腕部。2 例(2 只腕部)失访。患者在注射后中位 155 天报告了 31 只腕部的症状复发。19 只腕部在注射后中位 181 天接受了腕管松解术。没有患者接受重复注射。在我们的研究中,糖尿病患者在一年随访期内报告症状复发的风险增加了 2.6 倍。6 个月时无症状复发的生存率为 53%,12 个月时为 31%;6 个月时无重复干预的生存率为 81%,12 个月时为 66%。
单次注射在 6 周时使 79%的患者症状缓解;这些结果在 12 个月时保持在 31%的患者中。糖尿病患者症状复发的风险更高。